Imagen de Portada

Maternal Respiratory Syncytial Virus (RSV) Vaccination: Current Status and Comparison to Monoclonal Antibodies (mAbs) for RSV Prevention in Infants and Children

Guardado en:
Publicado en:Journal of Mother and Child vol. 29, no. 1 (2025), p. 93-101
Autor principal: Ahila, Ali
Otros Autores: Laiba, Shamim, Ibrahim, Ahmed, Humayun Muhammad Abdullah, Khan, Muhammad Hamza, Anum, Akbar, Jindal Sanmit, Shahzaib, Ahmed, Shrestha Jamuna, Nveed, Muhammad Abdullah
Publicado:
De Gruyter Brill Sp. z o.o., Paradigm Publishing Services
Materias:
Clinical trials
Infections
Monoclonal antibodies
Glycoproteins
Vaccines
Fatalities
Respiratory syncytial virus
Lung diseases
Age
Health care
Hospitalization
Medical research
Proteins
Acceso en línea:Citation/Abstract
Full Text + Graphics
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:Respiratory Syncytial Virus (RSV) causes over 50,000 hospitalizations annually among children under five years of age, leading to long-term consequences, such as asthma. Monoclonal antibodies (mAb) have been recommended for prevention, but their limitations have prompted the search for alternative preventive measures. The recent Food and Drug Administration (FDA) approval of a maternal RSV vaccine with 80% efficacy in protecting infants up to 90 days post-birth marks a significant advancement. Our narrative review investigates the differences in RSV immunization in pregnant mothers versus infants and children, with the goal of identifying factors that influence parental decisions. This study provides insights for optimising preventive strategies, and the results highlight the importance of maternal vaccination in combating RSV in children.
ISSN:2719-6488
2719-535X
1428-345X
2354-0060
DOI:10.34763/jmotherandchild.20252901.d-25-00012
Fuente:Health & Medical Collection